These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8957053)

  • 21. OKT3 for primary therapy of the first rejection episode in kidney transplants.
    Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM
    Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nursing guidelines for muromonab-CD3 (OKT3).
    Duffy MM; Nestor A
    ANNA J; 1992 Oct; 19(5):493-5. PubMed ID: 1456797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center.
    Oh HK; Provenzano R; Tayeb J; Satmary N; Jones B
    Clin Transplant; 1998 Aug; 12(4):343-7. PubMed ID: 9686329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation.
    Shield CF; Hughes JD
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
    Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
    Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy.
    Ciancio G; Carreno M; Mathew J; Ricordi C; Garcia R; Karatzas T; Fuller L; Cirocco R; Burke G; Webb M; Nery J; Tzakis A; Roth D; Esquenazi V; Miller J
    Transplant Proc; 1996 Apr; 28(2):943-4. PubMed ID: 8623473
    [No Abstract]   [Full Text] [Related]  

  • 28. Muromonab-CD3 and antithymocyte globulin in renal transplantation.
    Burk ML; Matuszewski KA
    Ann Pharmacother; 1997 Nov; 31(11):1370-7. PubMed ID: 9391693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of cyclosporine pharmacokinetic profiles in an antibody induction protocol reduces early acute rejection rates in recipients of primary cadaveric renal allografts.
    Lewis R; Coutee J; Steinmuller D; Hatch D; Manion S; Agrawal R; Moel D; Flanigan R
    Transplant Proc; 1997; 29(1-2):294-5. PubMed ID: 9123002
    [No Abstract]   [Full Text] [Related]  

  • 30. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation.
    Baker GM; Martin JE; Jang R; Schroeder TJ; Armitstead JA; Myre S; First MR
    Transplant Proc; 1998 Dec; 30(8):4082-4. PubMed ID: 9865304
    [No Abstract]   [Full Text] [Related]  

  • 32. A randomized multicenter trial of OKT3 mAbs induction compared with intravenous cyclosporine in pediatric renal transplantation.
    Benfield MR; Tejani A; Harmon WE; McDonald R; Stablein DM; McIntosh M; Rose S;
    Pediatr Transplant; 2005 Jun; 9(3):282-92. PubMed ID: 15910382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
    Bailey TC; Powderly WG; Storch GA; Miller SB; Dunkel JD; Woodward RS; Spitznagel E; Hanto DW; Dunagan WC
    Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-dose OKT3 for cadaveric renal transplantation.
    Schweizer RT; Roper L; Hull D; Bartus SA
    Transplant Proc; 1992 Dec; 24(6):2592-3. PubMed ID: 1465875
    [No Abstract]   [Full Text] [Related]  

  • 35. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation.
    D'Alessandro AM; Pirsch JD; Stratta RJ; Sollinger HW; Kalayoglu M; Maki DG; Belzer FO
    Transplantation; 1989 Feb; 47(2):297-300. PubMed ID: 2493176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients.
    Brennan DC; Schnitzler MA; Baty JD; Ceriotti CS; Lowell JA; Shenoy S; Howard TK; Woodward RS
    Pharmacoeconomics; 1997 Mar; 11(3):237-45. PubMed ID: 10165313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients.
    Thistlethwaite JR; Heffron TG; Stuart JK; Buckingham M; Stuart FP
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):28-34. PubMed ID: 2510508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3.
    Chowdhury S; Kode RK; Ranganna K; Damask AM; Lam A; Fyfe B; Stabler S; Kumar AM; Tomeny MB; Kumar MS; Pankewycz O
    Transplant Proc; 2001; 33(1-2):1057-8. PubMed ID: 11267189
    [No Abstract]   [Full Text] [Related]  

  • 39. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection.
    Cole EH; Cattran DC; Farewell VT; Aprile M; Bear RA; Pei YP; Fenton SS; Tober JA; Cardella CJ
    Transplantation; 1994 Jan; 57(1):60-7. PubMed ID: 8291115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consequences of OKT3 administration via continuous infusion as compared to bolus infusion.
    ten Berge RJ; Buysmann S; van Diepen FN; Surachno S; Hack CE
    Transplant Proc; 1996 Dec; 28(6):3217-20. PubMed ID: 8962246
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.